Iter-4360dd15-0048-crossref-trialish-candidate-extraction

本轮结果：用 Crossref references 替代 mmc1.pdf 镜像，抽取到可复现的临床候选集

本轮没有找到可打开的 mmc1.pdf 二次转载，但通过 DOI 10.1016/S2666-7568(23)00258-1 的 Crossref 机器可读 references，拿到了综述的 75 条参考文献数组，并用本地规则把候选压缩到人类临床文章。

可复现代码

import requests, re
doi='10.1016/S2666-7568(23)00258-1'
msg=requests.get(f'https://api.crossref.org/works/{doi}', timeout=30,
                 headers={'User-Agent':'Mozilla/5.0'}).json()['message']
refs=msg['reference']
kw = re.compile(r'rapamycin|sirolimus|everolimus|temsirolimus|rapalog|mTOR inhibitor|mammalian target of rapamycin', re.I)
trialish_markers = re.compile(r'trial|randomi[sz]ed|placebo|phase\s*[1-4]|crossover|double[- ]blind|pilot|feasibility|futility|extension|proof[- ]of[- ]concept|study', re.I)
animal = re.compile(r'fruit fly|drosophila|mouse|mice|rat|rats|murine|animal|in vivo', re.I)
items=[]
for i,r in enumerate(refs,1):
    txt=' | '.join(str(r.get(k,'')) for k in ['article-title','journal-title','author','DOI','unstructured'])
    if kw.search(txt) and trialish_markers.search(txt) and not animal.search(txt):
        items.append((i, r.get('article-title') or r.get('unstructured') or '', r.get('year') or '', r.get('DOI') or ''))
print('COUNT', len(items))
for i,t,y,d in items:
    print(f'{i}\t{y}\t{d}\t{t}')

目前得到的 14 条 human trial-ish 候选

- 25 10.1016/S2666-7568(21)00062-3 Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
- 26 10.1007/s00280-012-1845-7 A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults
- 33 10.1016/j.exger.2017.12.026 A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects
- 34 10.1016/j.ophtha.2011.07.034 A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema
- 35 10.1016/j.oret.2017.08.015 Treatment of geographic atrophy with intravitreal sirolimus: the Age-Related Eye Disease Study 2 ancillary study
- 38 10.1002/mds.28923 mTOR inhibition with sirolimus in multiple system atrophy: a randomized, double-blind, placebo-controlled futility trial and 1-year biomarker longitudinal analysis
- 39 10.1167/iovs.14-15877 Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial
- 40 10.1086/674311 Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial
- 41 10.1136/ard.2007.078808 Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
- 42 10.1155/2019/7684352 Low-dose sirolimus immunoregulation therapy in patients with active rheumatoid arthritis: a 24-week follow-up of the randomized, open-label, parallel-controlled trial
- 67 10.1016/S0140-6736(16)31419-2 Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
- 68 10.1212/CPJ.0000000000000514 Everolimus for treatment-refractory seizures in TSC: extension of a randomized controlled trial
- 69 10.1111/epi.17099 Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: results from the postextension phase of EXIST-3
- 70 10.1002/ijc.31738 Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: results of the single-arm, phase IIIB 4EVER trial

结论

- 这轮已经把“找镜像”替换成了更稳的机器可读引用链抽取。
- 结果与之前的 13 条口径接近，但严格按当前规则得到的是 14 条，因此下一步应做的是“家族去重 + 目标综述纳入标准核对”，而不是继续扩大搜索面。